Publication Name	World Journal of Diabetes
Manuscript ID	89226
Country	India

Received	2023-11-02 13:27
Peer-Review Started	2023-10-24 10:56
To Make the First Decision
Return for Revision	2023-12-19 00:44
Revised	2023-12-19 15:04
Second Decision	2024-01-23 08:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-01-30 08:39
Articles in Press	2024-01-30 08:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-05 09:26
Publish the Manuscript Online	2024-03-15 09:49

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Letter to the Editor
Article Title	Chiglitazar and Thiazolidinedione in patients with type 2 diabetes: Which is better?
Manuscript Source	Unsolicited Manuscript
All Author List	Kotha Sugunakar Reddy, Archana Gaur, Sakthivadivel Varatharajan and Arvind Kumar Morya
ORCID	Author(s) ORCID Number Sakthivadivel Varatharajan http://orcid.org/0000-0002-5691-670X Arvind Kumar Morya http://orcid.org/0000-0003-0462-119X
Funding Agency and Grant Number
Corresponding Author	Arvind Kumar Morya, MBBS, MNAMS, MS, Additional Professor, Department of Ophthalmology, All India Institute of Medical Sciences, Bibi Nagar, Hyderabad 508126, Telangana, India. bulbul.morya@gmail.com
Key Words	Type-II diabetes mellitus; Glucose intolerance; Hyperglycemia; Research methodology
Core Tip	The authors had done an indirect comparison between the new anti-diabetic drug Chiglitazar with Thiazolidinediones. It is premature to compare a single, relatively smaller study to 142 studies on Thiazolidinediones which are spanning over 28 years. Also, the efficacy of different thiazolidinediones has not been comprehensively compared and emphasized in the analysis and discussion.
Publish Date	2024-03-15 09:49
Citation	Reddy KS, Gaur A, Varatharajan S, Morya AK. Chiglitazar and Thiazolidinedione in patients with type 2 diabetes: Which is better? World J Diabetes 2024; 15(3): 565-567
URL	https://www.wjgnet.com/1948-9358/full/v15/i3/565.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i3.565

Full Article (PDF)	WJD-15-565-with-cover.pdf
Full Article (Word)	WJD-15-565.docx
Manuscript File	89226_Auto_Edited-YJP.docx
Answering Reviewers	89226-Answering reviewers.pdf
Audio Core Tip	89226-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	89226-Conflict-of-interest statement.pdf
Copyright License Agreement	89226-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	89226-Language certificate.pdf
Peer-review Report	89226-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	89226-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	89226-Bing-Lin C-2.png
Scientific Editor Work List	89226-Scientific editor work list.pdf
CrossCheck Report	89226-CrossCheck.png
CrossCheck Report	89226-CrossCheck report.pdf